BioCryst to Present at Barclays Global Healthcare Conference
February 28 2019 - 7:00AM
BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that
the company will present at the Barclays Global Healthcare
Conference in Miami Beach, Florida on Tuesday, March 12, 2019 at
8:00 a.m. ET.
Links to a live audio webcast and replay of the
presentation may be accessed in the Investors section of BioCryst’s
website at http://www.biocryst.com.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals discovers novel, oral small-molecule
medicines that treat rare diseases in which significant unmet
medical needs exist and an enzyme plays a key role in the
biological pathway of the disease. BioCryst has several ongoing
development programs of oral drugs for rare diseases including
BCX7353, an oral plasma kallikrein inhibitor for treatment of
hereditary angioedema; a preclinical program with an oral ALK-2
inhibitor for treatment of fibrodysplasia ossificans progressive,
and intravenous galidesivir, a broad-sepctrum viral RNA polymerase
inhibitor, as a potential treatment for Marburg virus disease and
Yellow Fever, under contracts from NIAID and HHS/BARDA. RAPIVAB®
(peramivir injection), an intravenous influenza virus neuraminidase
inhibitor for the treatment of influenza, is BioCryst's first
approved product and has received regulatory approval in the U.S.,
Canada, Australia, Japan, Taiwan, Korea and the European Union.
Post-marketing commitments for RAPIVAB are ongoing. For more
information, please visit the Company's website at
www.BioCryst.com.
BCRXW
Contact:John Bluth+1 919 859
7910jbluth@biocryst.com
BioCryst Pharmaceuticals (NASDAQ:BCRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
BioCryst Pharmaceuticals (NASDAQ:BCRX)
Historical Stock Chart
From Sep 2023 to Sep 2024